Phase I Trial of 90Y-DOTA-tyr 3-Octreotide in Children and Young AdultsAnis unavailable. This article is available as HTML full text and PDF.doi:10.1097/01.mpa.0000363936.21412.5dPancreas
“Raludotatug deruxtecan has shown promising activity in a Phase 1 trial of patients with advanced ovarian cancer,” said Mark Rutstein, MD, global head, oncology clinical development, Daiichi Sankyo. “The REJOICE-Ovarian01 trial, which is our first trial...
ProQR Therapeutic hasannounced its pivotal Phase 2/3Illuminatetrial of sepofarsen for the treatment ofCEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of Best Corrected Visual Acuity (BCVA) at Month 12. “Given the results observed i...
MAGNOLIA is an international multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study in patients with gastrointestinal (GI) / genitourinary (GU) cancer in whom DOAC treatment is not recommended. The st...
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “
The “Phase 2 randomized, double-blind, placebo-controlled crossover trial to evaluate the safety, tolerability, and efficacy of subcutaneous injections of elamipretide (MTP-131) in subjects with genetically confirmed Barth syndrome followed by an open-label treatment extension (SPIBA 201)” (Clinic...
The findings have been submitted for publication in a peer-reviewed journal. Please click on the below link for further ‘Notes to editors’ and ‘References’: https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/diabetes/new-positive-data-phase-iii-type-2-diabetes-trial...
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG...
The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer...
In order to address these challenges the following solutions have been implemented; a 2 week ‘wash out’ period to ensure clusters make a smooth transition from control to intervention phase; Dedicated trial management communication, forward planning and organisation of intervention training delivery; ...